Compare ROG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROG | NTLA |
|---|---|---|
| Founded | 1832 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1994 | 2016 |
| Metric | ROG | NTLA |
|---|---|---|
| Price | $131.20 | $13.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | ★ $133.00 | $20.45 |
| AVG Volume (30 Days) | 157.5K | ★ 3.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $879,091,000.00 | $67,671,000.00 |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $6.09 | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 7.07 | ★ 16.92 |
| 52 Week Low | $56.76 | $6.83 |
| 52 Week High | $131.76 | $28.24 |
| Indicator | ROG | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 74.45 | 48.16 |
| Support Level | $102.05 | $11.93 |
| Resistance Level | N/A | $14.32 |
| Average True Range (ATR) | 4.14 | 0.97 |
| MACD | 1.26 | 0.08 |
| Stochastic Oscillator | 88.42 | 24.88 |
Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.